Literature DB >> 27347437

Botulinum toxins in clinical practice: Gaps in knowledge.

Richard L Barbano1.   

Abstract

Year:  2016        PMID： 27347437      PMCID： PMC4909523          DOI： 10.1212/CPJ.0000000000000244

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  6 in total

Review 1.  Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.

Authors:  W H Jost; A Kohl
Journal:  J Neurol       Date:  2001-04       Impact factor: 4.849

2.  Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  David M Simpson; Mark Hallett; Eric J Ashman; Cynthia L Comella; Mark W Green; Gary S Gronseth; Melissa J Armstrong; David Gloss; Sonja Potrebic; Joseph Jankovic; Barbara P Karp; Markus Naumann; Yuen T So; Stuart A Yablon
Journal:  Neurology       Date:  2016-04-18       Impact factor: 9.910

Review 3.  Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.

Authors:  Mary Ann Chapman; Rich Barron; David C Tanis; Chandler E Gill; P David Charles
Journal:  Clin Ther       Date:  2007-07       Impact factor: 3.393

4.  Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.

Authors:  K Roger Aoki
Journal:  Toxicon       Date:  2002-07       Impact factor: 3.033

5.  Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.

Authors:  M F Brin; S Fahn; C Moskowitz; A Friedman; H M Shale; P E Greene; A Blitzer; T List; D Lange; R E Lovelace
Journal:  Mov Disord       Date:  1987       Impact factor: 10.338

6.  The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.

Authors:  Anthony J Batty; Ryan N Hansen; Lisa M Bloudek; Sepideh F Varon; Esther J Hayward; Becky W Pennington; Richard B Lipton; Sean D Sullivan
Journal:  J Med Econ       Date:  2013-05-22       Impact factor: 2.448
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.